Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

7.895 +0.255 (+3.34%)
Streaming Delayed Price Updated: 10:58 AM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Verastem, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
News headline image
Where Verastem Stands With Analysts ↗
 
Via Benzinga
News headline image
Analyst Ratings for Verastem ↗
 
Via Benzinga
News headline image
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
From Verastem Oncology
Via Business Wire
News headline image
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and... 
Via Benzinga
News headline image
3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024 ↗
Discover AI's top stock selections, meticulously analyzed for 2024, promising more than just returns but a revolution in your portfolio. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
From Verastem Oncology
Via Business Wire
News headline image
3 Off-the-Beaten-Path Stocks Poised for Substantial Growth ↗
Although there’s safety in numbers, many times, you need to consider uncommon stocks to buy for growth for robust upside. 
Via InvestorPlace
News headline image
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
News headline image
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential ↗
Although even so-called penny stocks with potential carry dramatic risks, these four-baggers benefit from analyst backing. 
Via InvestorPlace
News headline image
New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
News headline image
First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Strengthens Executive Leadership Team with Key Appointments
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
News headline image
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
From Verastem Oncology
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023 ↗
 
Via Benzinga
News headline image
Verastem Oncology to Participate in Upcoming Investor Conferences
From Verastem Oncology
Via Business Wire
News headline image
3 Penny Stocks That Can Triple Your Money in the Next 12 Months ↗
Although penny stocks are among the most speculative asset classes, these wagers just happen to have strong analyst backing. 
Via InvestorPlace
News headline image
Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal ↗
Shanghai GenFleet Technologies partnered three preclinical small-molecule candidates for RAS pathway-driven cancers to Verastem Oncology in a deal that could be worth up to $625.5 million. GenFleet... 
Via Talk Markets
News headline image
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
From Verastem Oncology
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.